CorMedix Inc. (NASDAQ:CRMD – Get Free Report) was up 3.3% on Wednesday after Truist Financial raised their price target on the stock from $12.00 to $17.00. Truist Financial currently has a buy rating on the stock. CorMedix traded as high as $12.45 and last traded at $12.44. Approximately 405,086 shares changed hands during trading, a decline of 37% from the average daily volume of 641,758 shares. The stock had previously closed at $12.04.
Several other equities research analysts have also recently weighed in on CRMD. Royal Bank of Canada reissued an “outperform” rating and issued a $9.00 price objective on shares of CorMedix in a research report on Thursday, August 15th. Needham & Company LLC reiterated a “buy” rating and set a $10.00 target price on shares of CorMedix in a research note on Thursday, August 15th. Finally, Rodman & Renshaw assumed coverage on shares of CorMedix in a research report on Monday, August 26th. They issued a “buy” rating and a $13.00 price target on the stock. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $13.60.
Read Our Latest Stock Analysis on CRMD
Institutional Inflows and Outflows
CorMedix Stock Up 2.6 %
The company has a market capitalization of $678.74 million, a price-to-earnings ratio of -13.28 and a beta of 1.61. The business has a fifty day simple moving average of $7.62 and a two-hundred day simple moving average of $5.84.
CorMedix (NASDAQ:CRMD – Get Free Report) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. The business had revenue of $0.81 million for the quarter, compared to analyst estimates of $0.75 million. During the same period in the prior year, the business earned ($0.25) earnings per share. As a group, equities analysts predict that CorMedix Inc. will post -0.58 earnings per share for the current fiscal year.
CorMedix Company Profile
CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Read More
- Five stocks we like better than CorMedix
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- What to Know About Investing in Penny Stocks
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.